Relationship Between Tumor and Peripheral Blood NPRL2 MRNA Levels in Patients with Colorectal Adenoma and Colorectal Cancer

Overview

Journal Cancer Biol Ther

Specialties Oncology
Pharmacology

Date 2014 Feb 14

PMID 24521741

Citations 6

Authors

Ai-Yun Liu

Dian-Ggang Liu

Ya-Ju Du

Feng-Hua Pei

Guang Yang

Bing-Rong Liu

Hui-Tao Zhang

Xin-Hong Wang

Yu-Jing Fan

Ying-zhun Chen

Yang Jiang

Jing Chen

Affiliations

Soon will be listed here.

Abstract

NPRL2 is a tumor suppressor gene involved in the progression of human cancer. The present study investigated whether NPRL2 expression correlates with colorectal cancer (CRC) progression. Colorectal tissue and peripheral blood samples were obtained from 62 patients with CRC, 38 patients with colorectal adenomas and 51 normal controls. NPRL2 mRNA levels in tissue samples and blood were measured using quantitative real-time PCR. NPRL2 protein expression was determined by immunohistochemistry. NPRL2 protein expression in CRCs was significantly lower than in the adenomas or normal colorectal tissue. NPRL2 mRNA expression was significantly decreased in adenomas compared with normal controls (P<0.0001) and it was further decreased in colorectal tumors compared with adenomas (P<0.0001). NPRL2 mRNA levels expression correlated with tumor stage. In addition, NPRL2 mRNA levels in the blood correlated with the levels detected in tumors. Furthermore, receiver operating characteristic (ROC) analysis showed that NPRL2 expression in blood could distinguish colorectal adenomas and CRCs from normal controls. NPRL2 mRNA expression in CRC tumor tissues and peripheral blood correlated with colorectal tumor progression. Based on our findings, we can conclude that NPRL2 mRNA blood levels could be a potentially useful marker for the detection of early stage adenomas and CRCs.

Citing Articles

gene therapy induces effective antitumor immunity in mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model.

Meraz I, Majidi M, Song R, Meng F, Gao L, Wang Q Elife. 2025; 13.

PMID: 39932765 PMC: 11813225. DOI: 10.7554/eLife.98258.

Structures and Functions of the Human GATOR1 Complex.

Ivanova I, Shen K Subcell Biochem. 2024; 104:269-294.

PMID: 38963491 DOI: 10.1007/978-3-031-58843-3_12.

Bioinformatics analysis of the prognostic and immunotherapeutic significance of NPRL2 in stomach adenocarcinoma.

Pi Y, Zhan Y, Song J, Jin X, Chen J J Gastrointest Oncol. 2022; 13(4):1589-1604.

PMID: 36092347 PMC: 9459220. DOI: 10.21037/jgo-22-115.

Nitrogen Permease Regulator-Like-2 Exhibited Anti-Tumor Effects And Enhanced The Sensitivity Of Colorectal Cancer Cells To Oxaliplatin And 5-Fluorouracil.

Liu A, Qiao J, He L, Liu Z, Chen J, Pei F Onco Targets Ther. 2019; 12:8637-8644.

PMID: 31695423 PMC: 6805118. DOI: 10.2147/OTT.S219562.

Overexpression of Nitrogen Permease Regulator Like-2 (NPRL2) Enhances Sensitivity to Irinotecan (CPT-11) in Colon Cancer Cells by Activating the DNA Damage Checkpoint Pathway.

Liu S, Liu B Med Sci Monit. 2018; 24:1424-1433.

PMID: 29519997 PMC: 5857147. DOI: 10.12659/msm.909186.

References

Schenk P, Brok M, Boersma A, Brandsma J, den Dulk H, Burger H . Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell kill. Mol Pharmacol. 2003; 64(2):259-68. DOI: 10.1124/mol.64.2.259. View

Chen H, Weng Y, Jiang B, Sheng J, Zheng P, Yu C . Epidemiological study of colorectal adenoma and cancer in symptomatic patients in China between 1990 and 2009. J Dig Dis. 2011; 12(5):371-8. DOI: 10.1111/j.1751-2980.2011.00531.x. View

Ferlay J, Parkin D, Steliarova-Foucher E . Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46(4):765-81. DOI: 10.1016/j.ejca.2009.12.014. View

Lo P, Leung A, Xiong W, Law S, Duh F, Lerman M . Expression of candidate chromosome 3p21.3 tumor suppressor genes and down-regulation of BLU in some esophageal squamous cell carcinomas. Cancer Lett. 2005; 234(2):184-92. DOI: 10.1016/j.canlet.2005.03.036. View

Guadagni F, Kantor J, Aloe S, Carone M, Spila A, DAlessandro R . Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to.... Cancer Res. 2001; 61(6):2523-32. View

Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C . Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res. 2002; 62(9):2715-20. PMC: 3478680. View

Sclafani F, Gullo G, Sheahan K, Crown J . BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications. Crit Rev Oncol Hematol. 2012; 87(1):55-68. DOI: 10.1016/j.critrevonc.2012.11.003. View

Andersen V, Holst R, Vogel U . Systematic review: diet-gene interactions and the risk of colorectal cancer. Aliment Pharmacol Ther. 2012; 37(4):383-91. PMC: 3565452. DOI: 10.1111/apt.12180. View

Wheeler J . Epigenetics, mismatch repair genes and colorectal cancer. Ann R Coll Surg Engl. 2005; 87(1):15-20. PMC: 1963859. DOI: 10.1308/1478708051423. View

10.

Yang X, Zhao J, Huang C, Wang Q, Pan K, Wang D . Decreased expression of the FOXO3a gene is associated with poor prognosis in primary gastric adenocarcinoma patients. PLoS One. 2013; 8(10):e78158. PMC: 3806843. DOI: 10.1371/journal.pone.0078158. View

11.

Xi L, Nicastri D, El-Hefnawy T, Hughes S, Luketich J, Godfrey T . Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem. 2007; 53(7):1206-15. DOI: 10.1373/clinchem.2006.081828. View

12.

Yogurtcu B, Hatemi I, Aydin I, Buyru N . NPRL2 gene expression in the progression of colon tumors. Genet Mol Res. 2012; 11(4):4810-6. DOI: 10.4238/2012.September.12.3. View

13.

Church D, Midgley R, Kerr D . Biomarkers in early-stage colorectal cancer: ready for prime time?. Dig Dis. 2012; 30 Suppl 2:27-33. DOI: 10.1159/000341890. View

14.

Creeden J, Junker F, Vogel-Ziebolz S, Rex D . Serum tests for colorectal cancer screening. Mol Diagn Ther. 2011; 15(3):129-41. DOI: 10.1007/BF03256403. View

15.

Luo Y, Wang L, Wang J . Developing proteomics-based biomarkers for colorectal neoplasms for clinical practice: opportunities and challenges. Proteomics Clin Appl. 2012; 7(1-2):30-41. DOI: 10.1002/prca.201200071. View

16.

Bretthauer M, Kalager M . Principles, effectiveness and caveats in screening for cancer. Br J Surg. 2012; 100(1):55-65. DOI: 10.1002/bjs.8995. View

17.

Li J, Wang F, Haraldson K, Protopopov A, Duh F, Geil L . Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C. Cancer Res. 2004; 64(18):6438-43. DOI: 10.1158/0008-5472.CAN-03-3869. View

18.

Jung K, Park S, Kong H, Won Y, Boo Y, Shin H . Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci. 2010; 25(8):1113-21. PMC: 2908777. DOI: 10.3346/jkms.2010.25.8.1113. View

19.

Jayachandran G, Ueda K, Wang B, Roth J, Ji L . NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway. PLoS One. 2010; 5(8):e11994. PMC: 2916838. DOI: 10.1371/journal.pone.0011994. View

20.

Ueda K, Kawashima H, Ohtani S, Deng W, Ravoori M, Bankson J . The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res. 2006; 66(19):9682-90. DOI: 10.1158/0008-5472.CAN-06-1483. View